232 related articles for article (PubMed ID: 27553708)
1. Stratification and therapeutic potential of PML in metastatic breast cancer.
Martín-Martín N; Piva M; Urosevic J; Aldaz P; Sutherland JD; Fernández-Ruiz S; Arreal L; Torrano V; Cortazar AR; Planet E; Guiu M; Radosevic-Robin N; Garcia S; Macías I; Salvador F; Domenici G; Rueda OM; Zabala-Letona A; Arruabarrena-Aristorena A; Zúñiga-García P; Caro-Maldonado A; Valcárcel-Jiménez L; Sánchez-Mosquera P; Varela-Rey M; Martínez-Chantar ML; Anguita J; Ibrahim YH; Scaltriti M; Lawrie CH; Aransay AM; Iovanna JL; Baselga J; Caldas C; Barrio R; Serra V; Vivanco Md; Matheu A; Gomis RR; Carracedo A
Nat Commun; 2016 Aug; 7():12595. PubMed ID: 27553708
[TBL] [Abstract][Full Text] [Related]
2. PML promotes metastasis of triple-negative breast cancer through transcriptional regulation of HIF1A target genes.
Ponente M; Campanini L; Cuttano R; Piunti A; Delledonne GA; Coltella N; Valsecchi R; Villa A; Cavallaro U; Pattini L; Doglioni C; Bernardi R
JCI Insight; 2017 Feb; 2(4):e87380. PubMed ID: 28239645
[TBL] [Abstract][Full Text] [Related]
3. PML at Mitochondria-Associated Membranes Is Critical for the Repression of Autophagy and Cancer Development.
Missiroli S; Bonora M; Patergnani S; Poletti F; Perrone M; Gafà R; Magri E; Raimondi A; Lanza G; Tacchetti C; Kroemer G; Pandolfi PP; Pinton P; Giorgi C
Cell Rep; 2016 Aug; 16(9):2415-27. PubMed ID: 27545895
[TBL] [Abstract][Full Text] [Related]
4. Promyelocytic leukemia protein (PML) controls breast cancer cell proliferation by modulating Forkhead transcription factors.
Sachini N; Arampatzi P; Klonizakis A; Nikolaou C; Makatounakis T; Lam EW; Kretsovali A; Papamatheakis J
Mol Oncol; 2019 Jun; 13(6):1369-1387. PubMed ID: 30927552
[TBL] [Abstract][Full Text] [Related]
5. NEMO, a Transcriptional Target of Estrogen and Progesterone, Is Linked to Tumor Suppressor PML in Breast Cancer.
Elsarraj HS; Valdez KE; Hong Y; Grimm SL; Ricci LR; Fan F; Tawfik O; May L; Cusick T; Inciardi M; Redick M; Gatewood J; Winblad O; Hilsenbeck S; Edwards DP; Hagan CR; Godwin AK; Fabian C; Behbod F
Cancer Res; 2017 Jul; 77(14):3802-3813. PubMed ID: 28515148
[TBL] [Abstract][Full Text] [Related]
6. PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies.
Iwanami A; Gini B; Zanca C; Matsutani T; Assuncao A; Nael A; Dang J; Yang H; Zhu S; Kohyama J; Kitabayashi I; Cavenee WK; Cloughesy TF; Furnari FB; Nakamura M; Toyama Y; Okano H; Mischel PS
Proc Natl Acad Sci U S A; 2013 Mar; 110(11):4339-44. PubMed ID: 23440206
[TBL] [Abstract][Full Text] [Related]
7. Dual regulation of Stat1 and Stat3 by the tumor suppressor protein PML contributes to interferon α-mediated inhibition of angiogenesis.
Hsu KS; Zhao X; Cheng X; Guan D; Mahabeleshwar GH; Liu Y; Borden E; Jain MK; Kao HY
J Biol Chem; 2017 Jun; 292(24):10048-10060. PubMed ID: 28432122
[TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide and angiotensin II have inhibitory effects on HERG protein expression: Evidence for the role of PML SUMOylation.
Liu Y; Li D; Nie D; Liu SK; Qiu F; Liu MT; Li YY; Wang JX; Liu YX; Dong CJ; Wu D; Tian W; Yang J; Mu W; Li JT; Zhao D; Wang XF; Chu WF; Yang BF
Oncotarget; 2017 Jul; 8(28):45447-45458. PubMed ID: 28525371
[TBL] [Abstract][Full Text] [Related]
9. Molecular targeting therapy against promyelocytic leukemia protein using arsenic acids in experimental intracranial medulloblastoma.
Gu C; Yokota N; Gao Y; Amano S; Koizumi S; Tokuyama T; Namba H
Neurol Med Chir (Tokyo); 2012; 52(2):62-7. PubMed ID: 22362285
[TBL] [Abstract][Full Text] [Related]
10. Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure.
Ablain J; Rice K; Soilihi H; de Reynies A; Minucci S; de Thé H
Nat Med; 2014 Feb; 20(2):167-74. PubMed ID: 24412926
[TBL] [Abstract][Full Text] [Related]
11. Targeting PML in triple negative breast cancer elicits growth suppression and senescence.
Arreal L; Piva M; Fernández S; Revandkar A; Schaub-Clerigué A; Villanueva J; Zabala-Letona A; Pujana M; Astobiza I; Cortazar AR; Hermanova I; Bozal-Basterra L; Arruabarrena-Aristorena A; Crespo JR; Valcarcel-Jimenez L; Zúñiga-García P; Canals F; Torrano V; Barrio R; Sutherland JD; Alimonti A; Martin-Martin N; Carracedo A
Cell Death Differ; 2020 Apr; 27(4):1186-1199. PubMed ID: 31570853
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner.
Wang ZG; Rivi R; Delva L; König A; Scheinberg DA; Gambacorti-Passerini C; Gabrilove JL; Warrell RP; Pandolfi PP
Blood; 1998 Sep; 92(5):1497-504. PubMed ID: 9716575
[TBL] [Abstract][Full Text] [Related]
13. Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth.
Zhou W; Cheng L; Shi Y; Ke SQ; Huang Z; Fang X; Chu CW; Xie Q; Bian XW; Rich JN; Bao S
Oncotarget; 2015 Nov; 6(35):37300-15. PubMed ID: 26510911
[TBL] [Abstract][Full Text] [Related]
14. Study of Arsenic Sulfide in Solid Tumor Cells Reveals Regulation of Nuclear Factors of Activated T-cells by PML and p53.
Ding W; Tong Y; Zhang X; Pan M; Chen S
Sci Rep; 2016 Jan; 6():19793. PubMed ID: 26795951
[TBL] [Abstract][Full Text] [Related]
15. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation.
Lallemand-Breitenbach V; Zhu J; Puvion F; Koken M; Honoré N; Doubeikovsky A; Duprez E; Pandolfi PP; Puvion E; Freemont P; de Thé H
J Exp Med; 2001 Jun; 193(12):1361-71. PubMed ID: 11413191
[TBL] [Abstract][Full Text] [Related]
16. Arsenite inhibits the function of CD133
Tang H; Jin Y; Jin S; Tan Z; Peng Z; Kuang Y
Tumour Biol; 2016 Oct; 37(10):14103-14115. PubMed ID: 27517564
[TBL] [Abstract][Full Text] [Related]
17. Promyelocytic leukemia protein induces arsenic trioxide resistance through regulation of aldehyde dehydrogenase 3 family member A1 in hepatocellular carcinoma.
Zhang X; Yang XR; Sun C; Hu B; Sun YF; Huang XW; Wang Z; He YF; Zeng HY; Qiu SJ; Cao Y; Fan J; Zhou J
Cancer Lett; 2015 Sep; 366(1):112-22. PubMed ID: 26118777
[TBL] [Abstract][Full Text] [Related]
18. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells.
Zheng X; Seshire A; Rüster B; Bug G; Beissert T; Puccetti E; Hoelzer D; Henschler R; Ruthardt M
Haematologica; 2007 Mar; 92(3):323-31. PubMed ID: 17339181
[TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide inhibits breast cancer cell growth via microRNA-328/hERG pathway in MCF-7 cells.
Wang Y; Wang L; Yin C; An B; Hao Y; Wei T; Li L; Song G
Mol Med Rep; 2015 Jul; 12(1):1233-8. PubMed ID: 25824027
[TBL] [Abstract][Full Text] [Related]
20. Death by arsenic: implications of PML sumoylation.
Mann KK; Miller WH
Cancer Cell; 2004 Apr; 5(4):307-9. PubMed ID: 15093537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
